Vivek Subbiah: The evolving landscape of tissue-agnostic therapies in precision oncology

Vivek Subbiah shared on X:

“Such a delight to share with in Open Access for all to read ‘The evolving landscape of tissue-agnostic therapies in precision oncology’, published in the highest impact factor journal in all of oncology – CA: A Cancer Journal for Clinicians.”

The evolving landscape of tissue-agnostic therapies in precision oncology

Authors: Vivek Subbiah, Mohamed A. Gouda, Bettina Ryll, Howard A. Burris III and Razelle Kurzrock.

Source: Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.